Search

Your search keyword '"Altorki, N K"' showing total 7 results
Start Over Author "Altorki, N K" Database OpenAIRE
7 results on '"Altorki, N K"'

2. Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC) : RADIANT trial

Author

O'Brien, MER, Eberhardt, Wilfried, Altorki, N. K., Spigel, D. R., Crino, L., Tsai, C. M., Cho, E. K., Kim, J. H., Szczesna, A., Hoffman, P. C., Burghuber, O., Keshavjee, S., Orlov, S., Serwatowski, P., Wang, J. Z., Foley, M. A., Horan, J. D., Park, J. W., Shepherd, F. A., Kelly, K., and Tarceva Radiant Investigator Grp

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Treatment duration, medicine.medical_treatment, Medizin, non-small cell lung cancer (NSCLC), medicine.disease, Placebo, respiratory tract diseases, Surgery, Oncology, medicine, In patient, Erlotinib, business, Adjuvant, medicine.drug
Abstract

7535 Background: We describe treatment duration and safety in the safety full analysis set (sFAS) and in the subset of pts with EGFR del19 and L858R mutations (EGFR M+). Methods: RADIANT was a rand...

Published
2014

3. A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC) : RADIANT results

Author

Kelly, K., Altorki, N. K., Eberhardt, Wilfried, O'Brien, MER, Spigel, D. R., Crino, L., Tsai, C. M., Kim, J. H., Cho, E. K., Szczesna, A., Burghuber, O., Hoffman, P. C., Keshavjee, S., Orlov, S., Serwatowski, P., Wang, J. Z., Foley, M. A., Horan, J. D., Park, J. W., Shepherd, F. A., and Tarceva Radiant Investigator Grp

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Medizin, non-small cell lung cancer (NSCLC), medicine.disease, Placebo, Surgery, Internal medicine, medicine, Clinical endpoint, Immunohistochemistry, Adenocarcinoma, Erlotinib, Stage (cooking), business, Adjuvant, medicine.drug
Abstract

7501 Background: The proven efficacy of E in advanced NSCLC warranted its evaluation in the adjuvant setting. BR.21 data suggested pts with EGFR positive tumors (IHC/FISH) were more likely to benefit from E. Methods: Completely resected IB-IIIA NSCLC pts were randomized 2:1 to receive E 150 mg qd or P for 2 years. Pts were stratified according to stage, histology, prior adjuvant chemotherapy, smoking status, EGFR FISH status, and country. The primary endpoint was disease free survival (DFS) in the full analysis set (FAS). Secondary endpoints included overall survival (OS) in the FAS and DFS and OS in the EGFR mutation (EGFR M+) subset (del19/L858R). Hierarchical testing procedure was used. Results: Between NOV 2007 and JUL 2010, 973 pts were randomized. Baseline characteristics were balanced between arms (age > 65 41%; female 41%; stage IB 51%, II 33%, IIIA 16% [AJCC 6th ed]; adenocarcinoma 59%; prior adjuvant chemotherapy 53%; never smoker 20%; Asian 17%; EGFR FISH+ 72% and EGFR M+ 16.5%). The planned nu...

Published
2014

4. Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial

Author

Shepherd, F. A., Altorki, N. K., Eberhardt, Wilfried, O'Brien, Mary, Spigel, D. R., Crino, L., Tsai, C. M., Kim, J. H., Cho, E. K., Szczesna, A., Burghuber, O., Hoffman, P. C., Keshavjee, S., Orlov, S., Serwatowski, P., Wang, J. Z., Foley, M. A., Horan, J. D., Richardson, F. C., Kelly, K., and Tarceva Radiant Investigator Grp

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Medizin, non-small cell lung cancer (NSCLC), macromolecular substances, Placebo, medicine.disease, respiratory tract diseases, carbohydrates (lipids), stomatognathic diseases, Exon, Egfr tki, Internal medicine, Immunology, otorhinolaryngologic diseases, medicine, Erlotinib, business, Adjuvant, medicine.drug
Abstract

7513 Background: E, anEGFR TKI, prolongs survival in pts with advanced NSCLC. Pts with tumors carrying EGFR exon 19 del or 21 L858R mutations are particularly sensitive to EGFR TKIs. Methods: RADIA...

Published
2014

5. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer

Author

Wilbertz, T, Wagner, P, Petersen, K, Stiedl, A C, Scheble, V J, Maier, S, Reischl, M, Mikut, R, Altorki, N K, Moch, H, Fend, F, Staebler, A, Bass, A J, Meyerson, M, Rubin, M A, Soltermann, A, Lengerke, C, Perner, S, University of Zurich, and Perner, S

Subjects
2734 Pathology and Forensic Medicine, 10049 Institute of Pathology and Molecular Pathology, 610 Medicine & health
Published
2011

Catalog

Books, media, physical & digital resources
See catalog results